Below are the most recent publications written about "Benzimidazoles" by people in Profiles.
-
Sil S, Hussain A, Das Sarma J, Gupta P. Cyclometalated Iridium(III) Complex with Substituted Benzimidazole: pH Directed Organelle-Specific Localization Within Lysosome. Chembiochem. 2024 Dec 16; 25(24):e202400597.
-
Lin X, Soni A, Hessenow R, Sun Y, Mladenov E, Guberina M, Stuschke M, Iliakis G. Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Pol? inhibition. Radiother Oncol. 2024 Nov; 200:110475.
-
De Vrieze LM, Walton SE, Pottie E, Papsun D, Logan BK, Krotulski AJ, Stove CP, Vandeputte MM. In vitro structure-activity relationships and forensic case series of emerging 2-benzylbenzimidazole 'nitazene' opioids. Arch Toxicol. 2024 09; 98(9):2999-3018.
-
Velagapudi UK, Rouleau-Turcotte ?, Billur R, Shao X, Patil M, Black BE, Pascal JM, Talele TT. Novel modifications of PARP inhibitor veliparib increase PARP1 binding to DNA breaks. Biochem J. 2024 03 20; 481(6):437-460.
-
Ch?nard-Poirier M, Hansen AR, Gutierrez ME, Rasco D, Xing Y, Chen LC, Zhou H, Webber AL, Freshwater T, Sharma MR. A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors. Invest New Drugs. 2024 Jun; 42(3):241-251.
-
Gerratana L, Kocherginsky M, Davis AA, D'Amico P, Reduzzi C, Puglisi F, Cristofanilli M. Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial. Oncologist. 2024 Feb 02; 29(2):123-131.
-
Calello DP, Aldy K, Jefri M, Nguyen TT, Krotulski A, Logan B, Brent J, Wax P, Walton S, Manini AF. Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose. Clin Toxicol (Phila). 2022 09; 60(9):1067-1069.
-
Tanaka Y, Hino H, Takeya K, Eto M. Abemaciclib and Vacuolin-1 induce vacuole-like autolysosome formation - A new tool to study autophagosome-lysosome fusion. Biochem Biophys Res Commun. 2022 07 23; 614:191-197.
-
Brose MS, Pryma DA, Newbold KL. Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study. J Clin Oncol. 2022 06 10; 40(17):1847-1849.
-
Vandeputte MM, Krotulski AJ, Walther D, Glatfelter GC, Papsun D, Walton SE, Logan BK, Baumann MH, Stove CP. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid. Arch Toxicol. 2022 06; 96(6):1845-1863.